Previous close | 11.25 |
Open | 11.30 |
Bid | 11.64 x 500 |
Ask | 11.72 x 100 |
Day's range | 11.30 - 11.99 |
52-week range | 7.21 - 16.88 |
Volume | |
Avg. volume | 437,742 |
Market cap | 492.337M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.12 |
Earnings date | 05 Jul 2024 - 09 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 29.80 |
CAMBRIDGE, Mass. & SALISBURY, England, May 31, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that late-breaking data from the pivotal phase 3 KONFIDENT trial and open label KONFIDENT-S extension trial evaluating the efficacy and safety of sebetralstat were presented as late-breaking presentations at the European Academy of Allergy and Clinical Immunology Congress 2024. The results of KONFIDENT were simultaneously published in The New England Journal of Medicine.
CAMBRIDGE, Mass. & SALISBURY, England, May 24, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts and a symposium at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 taking place in Valencia, Spain from May 31-June 3.
KalVista Pharmaceuticals, Inc. ( NASDAQ:KALV ) is possibly approaching a major achievement in its business, so we would...